EMERALD HEALTH THERAPEUTICS INC ("EMH")
BULLETIN TYPE: Prospectus-Unit Offering
BULLETIN DATE: May 4, 2017
TSX Venture Tier 2 Company
Effective May 3, 2017, the Company's Short Form Base Shelf Prospectus dated January 25, 2017 and Prospectus Supplement dated April 12, 2017 was filed with and accepted by TSX Venture Exchange, and filed with and receipted by the Securities Commissions of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Newfoundland and Labrador, New Brunswick, Prince Edward Island and Nova Scotia, pursuant to the provisions of the Securities Act of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Newfoundland and Labrador, New Brunswick, Prince Edward Island and Nova Scotia.
TSX Venture Exchange has been advised that closing occurred on April 20, 2017 and April 21, 2017, for gross proceeds of $27,123,423.
Agents: Eight Capital
Offering: 13,170,000 units, 1,465,100 common shares and 987,750 warrants. Each unit consisting of one share and one-half of one warrant. Each whole warrant is exercisable into one common share (a "Warrant Share") of the Company at an exercise price of $2.60 per warrant share for up to 24 months following closing.
Unit Price: $1.85 per unit, $1.755 per share and $0.095 per warrant
Warrant Exercise Price/Term: $2.60 per share to April 20, 2019.
Agents' Options: 439,053 non-transferable compensation options exercisable to purchase one unit at $1.85 per unit ("Agent Unit") to April 20, 2019. Each Agent Unit has the same terms as the offering units.
For further information, please see the Company's news release dated April 10, 2017, April 11, 2017, April 20, 2017 and April 21, 2017.
________________________________________
|
|
